Daclatasvir

BreastfeedingPediatric

FDA APPROVAL DATE: 07/24/2015

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, Carbamazepine, Dabigatran, Phenytoin, Rifampin, St John's Wort

PREGNANCY CATEGORY: N/A
No data available

See also separate entry for sofosbuvir.

Our database has 45 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
RENAL
RESPIRATORY
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of daclatasvir in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 08/29/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top